OraSure files 510(k) for drugs-of-abuse diagnostic:
This article was originally published in Clinica
OraSure Technologies has filed a 510(k) application with the US FDA for permission to market its point-of-care oral fluid drugs-of-abuse diagnostic system. The UPlink reader has been submitted to the agency together with assays for detecting cocaine, opiates and amphetamines. The Bethlehem, Pennsylvania company plans to submit two additional tests - for marijuana and phencyclidine - within the next two months. The UPlink system is also being developed for gastrointestinal and respiratory infectious disease testing under an agreement with Meridian Diagnostics.
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.